 Patients with HCC who received curative liver resection R0and with positive expression of HAb18GCD147 in the HCC tissues were randomly assigned 1:1 by the doctors to receive placebocontrol group or Licartin treatment group. All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection. The outcomes of patients were evaluated during the 3-years follow up. 